E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Human epidermal growth factor receptor 2 (HER2)- expressing advanced colorectal cancer |
Cáncer colorrectal avanzado que expresa el receptor 2 del factor de crecimiento epidérmico humano (HER2) |
|
E.1.1.1 | Medical condition in easily understood language |
Human epidermal growth factor receptor 2 (HER2)- expressing advanced colorectal cancer |
Cáncer colorrectal avanzado que expresa el receptor 2 del factor de crecimiento epidérmico humano (HER2) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010029 |
E.1.2 | Term | Colorectal cancer NOS |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the objective response rate (ORR) of DS-8201a in HER2-expressing advanced metastatic colorectal cancer patients |
• Determinar la tasa de respuesta objetiva (TRO) de DS-8201a en pacientes con cáncer colorrectal con metástasis avanzado que expresa HER2. |
|
E.2.2 | Secondary objectives of the trial |
•To evaluate duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). ORR assessed by the investigator is also evaluated. •To evaluate the safety of DS-8201a •To determine the pharmacokinetics (PK) of DS-8201a |
• Evaluar la duración de la respuesta (DR), la tasa de control de la enfermedad (TCE), la supervivencia libre de progresión (SLP) y la supervivencia global (SG). También se analiza la TRO evaluada por el investigador. • Evaluar la seguridad de DS-8201a • Determinar la farmacocinética (FC) de DS-8201a |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Has pathologically documented unresectable, recurrent, or metastatic colorectal adenocarcinoma (until sponsor's notification to the study sites, subject must be a RAS/BRAF wild-type cancer) - Has received at least 2 prior regimens of standard treatment - Has measurable disease assessed by the investigator based on RECIST version 1.1. - Has an Eastern Cooperative Oncology Group Performance Status (ECOGPS) of 0 to 1 |
- Tiene un adenocarcinoma colorrectal irresecable, recurrente o metastático documentado mediante patología. Hasta que el promotor no notifique a los centros del estudio, el sujeto debe presentar cáncer RAS/ homólogo B1 del oncogén del sarcoma viral murino v-raf (BRAF). - Ha recibido al menos 2 pautas anteriores de tratamiento de referencia. - Tiene lesión cuantificable evaluada por el investigador según los Criterios de evaluación de la respuesta en tumores sólidos RECIST versión 1.1. - Presenta un estado funcional del Grupo Oncológico Cooperativo de la Costa Este de los EE. UU. (ECOG PS) de 0 a 1. |
|
E.4 | Principal exclusion criteria |
- Has a medical history of myocardial infarction within 6 months, symptomatic congestive heart failure - Has a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. - Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy |
- Tiene historia clínica de infarto de miocardio en los 6 meses anteriores a la inclusión, insuficiencia cardíaca congestiva sintomática - Tiene antecedentes de enfermedad pulmonar intersticial/neumonitis (no infecciosa) que ha requerido tratamiento con esteroides, presenta enfermedad pulmonar intersticial/neumonitis actualmente o no puede descartarse una sospecha de enfermedad pulmonar intersticial/neumonitis con las imágenes obtenidas en la selección. - Presenta compresión medular o metástasis en el sistema nervioso central clínicamente activa, que se define como no tratada y sintomática, o que requiere tratamiento |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Objective response rate (ORR) per imaging assessment - Percentage of participants with objective response per independent central imaging facility review based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 |
Tasa de respuesta objetiva (TRO) evaluada mediante revisión por la imagen_Porcentaje de participantes con respuesta objetiva por parte del centro de estudios por la imagen central e independiente en función de RECIST versión 1.1 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
every 6 weeks |
cada 6 semanas |
|
E.5.2 | Secondary end point(s) |
・Progression-free survival ・Overall survival ・Duration of response ・Disease control rate (DCR) ・ORR assessed by the investigator based on RECIST version 1.1 The following apply to categories; DS-8201a, total anti-HER2 antibody, and MAAA-1181a ・Maximum serum/plasma concentration (Cmax) ・ Time to Cmax (Tmax) ・Area under the concentration-time curve (AUC) ・AUC from the time of dosing until day 21 (AUC0-21d) |
- Supervivencia libre de progresión - Supervivencia global - Duración de la respuesta - Tasa de control de la enfermedad (TCE) - TRO evaluada por el investigador en función de RECIST versión 1.1. Los siguientes aplican a las categorías DS-8201a, anticuerpo anti-HER2 total y MAAA-1181a: - Máxima concentración suero/plasma Cmáx - Tiempo a la Cmáx (Tmáx) - Área bajo la curva concentración –tiempo (ABC) - ABC0 desde el momento de la dosis hasta el dia 21 (AUC0-21d) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
every 6 weeks for efficacy, OS for until death or last contact with subject |
cada 6 semanas para la eficacia, SG hasta defunción o ultimo contacto con el paciente |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Italy |
Japan |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of OS follow-up |
Fin del seguimiento de la SG |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |